Sara Redondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara Redondo has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Rodrigo Martino
Hematology Department, Hospital de la Sant Creu i Sant Pau. IR‐Sant Pau and José Carreras Leukemia Research Institutes Universitat Autónoma de Barcelona Bellaterra Spain
9 shared publicationsJavier Briones
Hematology Service Hospital de la Sant Creu i Sant Pau, IR‐Sant Pau and José Carreras Leukemia Research Institutes, Universitat Autónoma de Barcelona Barcelona Spain
8 shared publications- Irene García-Cadenas
Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau and Jose Carreras Leukemia Research Institutes, Autonomous University of Barcelona, Barcelona, Spain
7 shared publications - Albert Esquirol
Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain
6 shared publications Ana Garrido
Hematology Department, Hospital de la Sant Creu i Sant Pau. IR‐Sant Pau and José Carreras Leukemia Research Institutes Universitat Autónoma de Barcelona Bellaterra Spain
6 shared publicationsJorge Sierra
Hematology Department, Hospital de la Santa Creu i Sant Pau. IIB‐Sant Pau and José Carreras Leukemia Research Institutes. Medicine Department Universidad Autónoma de Barcelona Barcelona Spain
6 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in European Journal of Haematology
Association Between the Time of Day of Post‐Transplant Cyclophosphamide Administration and Haemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation
Objective: To evaluate the impact of the time‐of‐day (daytime vs. nighttime) of the infusion of post‐transplantation cyclophosphamide (PTCy) on the occurrence of haemorrhagic cystitis (HC) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo‐HSCT). Methods: We conducted a retrospective, single‐centre cohort study including adult allo‐HSCT between January 2014 and December 2022. All patients received PTCy at a dose of 50 mg/kg/day for two consecutive days. Patients were classified according to the timing of the first PTCy dose: daytime (06:00–17:59) or nighttime (18:00–05:59). The primary endpoint was the incidence of Grade II–IV HC. Results: A total of 178 patients were included. Grade II–IV HC occurred in 16.4% and 31.2% of patients following daytime and nighttime administration, respectively (OR 2.31, 95% CI 0.97–5.49; p = 0.079). After adjustment for potential confounders, nighttime administration was associated with higher odds of Grade II–IV HC (adjusted OR 2.82, 95% CI 1.12–7.10; p = 0.028). Grade III–IV HC was more frequent following nighttime administration (4.8% vs. 15.6%; OR 3.68, 95% CI 1.09–12.45; p = 0.043). No significant differences were observed in transplant outcomes. Conclusions: Nighttime administration of PTCy was associated with a numerically higher incidence of Grade II–IV HC, although the unadjusted primary analysis did not reach conventional statistical significance. This association was statistically significant after adjustment for potential confounders. No detectable differences in transplant outcomes were observed. These findings support prospective evaluation of chronomodulated PTCy administration as a simple, potentially modifiable strategy for reducing treatment‐related toxicity after allo‐HSCT.
- 14 October 2026
- Published by Wiley in European Journal of Haematology
Open AccessAssociation Between the Time of Day of Post‐Transplant Cyclophosphamide Administration and Haemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation
Objective: To evaluate the impact of the time‐of‐day (daytime vs. nighttime) of the infusion of post‐transplantation cyclophosphamide (PTCy) on the occurrence of haemorrhagic cystitis (HC) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo‐HSCT). Methods: We conducted a retrospective, single‐centre cohort study including adult allo‐HSCT between January 2014 and December 2022. All patients received PTCy at a dose of 50 mg/kg/day for two consecutive days. Patients were classified according to the timing of the first PTCy dose: daytime (06:00–17:59) or nighttime (18:00–05:59). The primary endpoint was the incidence of Grade II–IV HC. Results: A total of 178 patients were included. Grade II–IV HC occurred in 16.4% and 31.2% of patients following daytime and nighttime administration, respectively (OR 2.31, 95% CI 0.97–5.49; p = 0.079). After adjustment for potential confounders, nighttime administration was associated with higher odds of Grade II–IV HC (adjusted OR 2.82, 95% CI 1.12–7.10; p = 0.028). Grade III–IV HC was more frequent following nighttime administration (4.8% vs. 15.6%; OR 3.68, 95% CI 1.09–12.45; p = 0.043). No significant differences were observed in transplant outcomes. Conclusions: Nighttime administration of PTCy was associated with a numerically higher incidence of Grade II–IV HC, although the unadjusted primary analysis did not reach conventional statistical significance. This association was statistically significant after adjustment for potential confounders. No detectable differences in transplant outcomes were observed. These findings support prospective evaluation of chronomodulated PTCy administration as a simple, potentially modifiable strategy for reducing treatment‐related toxicity after allo‐HSCT.
- 23 July 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 413-422
Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation
Objective: This retrospective, single‐center study aims to compare the efficacy and safety of a reduced dose of post‐transplantation cyclophosphamide (PTCy) (60 mg/kg total dose) versus the standard dose (100 mg/kg total dose), both combined with tacrolimus, in adult patients undergoing allogeneic hematopoietic stem cell transplantation from HLA‐matched related or unrelated donors.Methods: We report clinical outcomes of 59 consecutive patients who received standard doses of PTCy and 48 with the new reduced dose.Results: Neutrophil and platelet recovery occurred later in the standard‐dose group (p < 0.01). The incidence of febrile neutropenia was higher in the standard‐dose group (p < 0.01). No significant differences were found in the incidence of acute cardiac events, early bacteremia, CMV reactivation within the first 100 days post‐HSCT, or the development of hemorrhagic cystitis. There were no significant differences in the incidence of grade II–IV and III–IV acute GvHD, moderate‐to‐severe chronic GvHD, or in 20‐month overall survival and progression‐free survival (p > 0.05). Non‐relapse mortality at 100 days and at 1 year was comparable between groups, as was 1‐year GVHD‐free/relapse‐free and immunosuppression‐free survival (p > 0.05).Conclusions: Reduced doses of CyPT combined with a single immunosuppressive agent are emerging as a safe and effective alternative for adult patients undergoing allo‐HSCT from HLA‐matched donors. Our findings support that this approach preserves key clinical outcomes while potentially reducing acute hematological and infectious toxicity.
- 23 July 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 413-422
Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation
Objective: This retrospective, single‐center study aims to compare the efficacy and safety of a reduced dose of post‐transplantation cyclophosphamide (PTCy) (60 mg/kg total dose) versus the standard dose (100 mg/kg total dose), both combined with tacrolimus, in adult patients undergoing allogeneic hematopoietic stem cell transplantation from HLA‐matched related or unrelated donors.Methods: We report clinical outcomes of 59 consecutive patients who received standard doses of PTCy and 48 with the new reduced dose.Results: Neutrophil and platelet recovery occurred later in the standard‐dose group (p < 0.01). The incidence of febrile neutropenia was higher in the standard‐dose group (p < 0.01). No significant differences were found in the incidence of acute cardiac events, early bacteremia, CMV reactivation within the first 100 days post‐HSCT, or the development of hemorrhagic cystitis. There were no significant differences in the incidence of grade II–IV and III–IV acute GvHD, moderate‐to‐severe chronic GvHD, or in 20‐month overall survival and progression‐free survival (p > 0.05). Non‐relapse mortality at 100 days and at 1 year was comparable between groups, as was 1‐year GVHD‐free/relapse‐free and immunosuppression‐free survival (p > 0.05).Conclusions: Reduced doses of CyPT combined with a single immunosuppressive agent are emerging as a safe and effective alternative for adult patients undergoing allo‐HSCT from HLA‐matched donors. Our findings support that this approach preserves key clinical outcomes while potentially reducing acute hematological and infectious toxicity.
- 11 December 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (3) , 353-362
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.
- 11 December 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (3) , 353-362
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.
- 15 November 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (3) , 436-442
Development and Clinical Validation of Liquid Chromatography–Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid‐Refractory Graft‐Versus‐Host Disease: A First Step Towards Optimized Treatment
Objective: This non‐interventional, prospective, single‐center study aimed to develop a technique to measure ruxolitinib (RUX) concentrations and provide preliminary data on the distribution of plasma drug levels in patients with steroid refractory (SR) GvHD.Methods: Between April 2023 and May 2024, we analyzed 48 blood samples from 29 patients with SR‐GvHD.Results: Median individual plasma concentrations varied across different RUX doses and largely overlapped: 39.2 ng/mL at 10 mg b.i.d (range: 0–73), 13.1 ng/mL at 10–5 mg (range, 6.1–35.6), and 31.6 ng/mL at 5 mg b.i.d (range: 0.7–99.9). Samples taken under non‐optimal temperature conditions showed a lower median concentration of 0.77 ng/mL (range: 0–7.4 ng/mL). The four patients who did not respond at days +28 and +180 after RUX initiation (3 with lower gastrointestinal aGvHD, and 1 with ocular, hepatic, and pulmonary cGvHD) showed a median concentration of only (7.4 ng/mL (range, 0–29) ng/mL) with full dosing.Conclusions: The introduction and validation of a liquid chromatography–tandem mass spectrometry method for quantifying plasma RUX concentrations was feasible in our center. Administering predetermined and fixed doses of RUX in patients with SR‐GvHD showed highly variable and overlapping plasma drug concentrations. This underscores the potential importance of RUX‐ pharmacokinetics (PK) monitoring.
- 15 November 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (3) , 436-442
Development and Clinical Validation of Liquid Chromatography–Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid‐Refractory Graft‐Versus‐Host Disease: A First Step Towards Optimized Treatment
Objective: This non‐interventional, prospective, single‐center study aimed to develop a technique to measure ruxolitinib (RUX) concentrations and provide preliminary data on the distribution of plasma drug levels in patients with steroid refractory (SR) GvHD.Methods: Between April 2023 and May 2024, we analyzed 48 blood samples from 29 patients with SR‐GvHD.Results: Median individual plasma concentrations varied across different RUX doses and largely overlapped: 39.2 ng/mL at 10 mg b.i.d (range: 0–73), 13.1 ng/mL at 10–5 mg (range, 6.1–35.6), and 31.6 ng/mL at 5 mg b.i.d (range: 0.7–99.9). Samples taken under non‐optimal temperature conditions showed a lower median concentration of 0.77 ng/mL (range: 0–7.4 ng/mL). The four patients who did not respond at days +28 and +180 after RUX initiation (3 with lower gastrointestinal aGvHD, and 1 with ocular, hepatic, and pulmonary cGvHD) showed a median concentration of only (7.4 ng/mL (range, 0–29) ng/mL) with full dosing.Conclusions: The introduction and validation of a liquid chromatography–tandem mass spectrometry method for quantifying plasma RUX concentrations was feasible in our center. Administering predetermined and fixed doses of RUX in patients with SR‐GvHD showed highly variable and overlapping plasma drug concentrations. This underscores the potential importance of RUX‐ pharmacokinetics (PK) monitoring.
- 18 August 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (6) , 776-787
Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation
Objective: This retrospective single center study aims to describe changes in the severity and organ‐specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.Methods: Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA‐matched or 1‐allele mismatched related or unrelated donors. Fifty‐eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort‐1), 87 (38%) tacrolimus plus sirolimus (Cohort‐2), and 81 (36%) post‐transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort‐3).Results: The incidence of grade II‐IV aGvHD was 69% vs. 41.4% vs. 27.2%; p < .01. The most significant reduction with PTCy was observed in both stage 3–4 skin and lower gastrointestinal (GI) involvement (p < .01). The incidence of moderate‐to‐severe cGvHD at 12 months was 34.5% vs. 34.5% vs. 6.2%; p < .01. Moderate‐to‐severe skin and GI cGvHD was less common after PTCy (p < .01). The 1‐year GvHD‐free/relapse‐free survival was higher with PTCy (p < .01).Conclusions: Our study indicates that PTCy‐based GvHD prophylaxis reduces the frequency and severity of both acute and chronic GvHD, with a notable decrease in severe GI and cutaneous manifestations. The higher GRFS may result in lower GvHD‐related mortality, leading to an improved quality of life among survivors.
- 18 August 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (6) , 776-787
Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation
Objective: This retrospective single center study aims to describe changes in the severity and organ‐specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.Methods: Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA‐matched or 1‐allele mismatched related or unrelated donors. Fifty‐eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort‐1), 87 (38%) tacrolimus plus sirolimus (Cohort‐2), and 81 (36%) post‐transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort‐3).Results: The incidence of grade II‐IV aGvHD was 69% vs. 41.4% vs. 27.2%; p < .01. The most significant reduction with PTCy was observed in both stage 3–4 skin and lower gastrointestinal (GI) involvement (p < .01). The incidence of moderate‐to‐severe cGvHD at 12 months was 34.5% vs. 34.5% vs. 6.2%; p < .01. Moderate‐to‐severe skin and GI cGvHD was less common after PTCy (p < .01). The 1‐year GvHD‐free/relapse‐free survival was higher with PTCy (p < .01).Conclusions: Our study indicates that PTCy‐based GvHD prophylaxis reduces the frequency and severity of both acute and chronic GvHD, with a notable decrease in severe GI and cutaneous manifestations. The higher GRFS may result in lower GvHD‐related mortality, leading to an improved quality of life among survivors.
- Open Access
- 6 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (10) , 1025.e1-1025.e14
Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil
- 6 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (10) , 1025.e1-1025.e14
Open AccessComparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil
- Open Access
- 22 July 2024
- Published by Springer Nature in Research Square
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Long-Term Experience in a Multi-Centre Study for Adult and Pediatric Patients, on Behalf of GETH-TC
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥ 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-centre study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favourable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.
- 22 July 2024
- Published by Springer Nature in Research Square
Open AccessRuxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Long-Term Experience in a Multi-Centre Study for Adult and Pediatric Patients, on Behalf of GETH-TC
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥ 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-centre study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favourable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.
- 15 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (10) , 1655-1661
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center
Treatment of chronic lymphocytic leukemia (CLL) has dramatically evolved over the last decades thanks to the introduction of targeted therapies. We aimed to describe retrospectively the evolution in the frontline prescription in the CLL patients from our institution. As a secondary objective, the impact of frontline therapy on the time-to-next-treatment (TTNT) and overall survival (OS). After a median of 6.4 years (0.1-36.4) of follow-up from diagnosis, 323 of 780 CLL patients (41.4%) required therapy. Alkylating agents in monotherapy (chlorambucil) were the most used until 2012, and from then, chemoimmunotherapy. Since 2018, targeted therapies were the most common therapeutic strategy (74.1%). Patients who received targeted therapies had significantly longer TTNT compared to other regimens. In the multivariable analyses, mutated IGHV genes targeted therapies and chemoimmunotherapy regimens were related to longer TTNT, and sex female, age younger than 65, and mutated IGHV genes were associated with better OS.
- 15 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (10) , 1655-1661
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center
Treatment of chronic lymphocytic leukemia (CLL) has dramatically evolved over the last decades thanks to the introduction of targeted therapies. We aimed to describe retrospectively the evolution in the frontline prescription in the CLL patients from our institution. As a secondary objective, the impact of frontline therapy on the time-to-next-treatment (TTNT) and overall survival (OS). After a median of 6.4 years (0.1-36.4) of follow-up from diagnosis, 323 of 780 CLL patients (41.4%) required therapy. Alkylating agents in monotherapy (chlorambucil) were the most used until 2012, and from then, chemoimmunotherapy. Since 2018, targeted therapies were the most common therapeutic strategy (74.1%). Patients who received targeted therapies had significantly longer TTNT compared to other regimens. In the multivariable analyses, mutated IGHV genes targeted therapies and chemoimmunotherapy regimens were related to longer TTNT, and sex female, age younger than 65, and mutated IGHV genes were associated with better OS.
- Open Access
- 20 April 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (7) , 473.e1-473.e6
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature
- 20 April 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (7) , 473.e1-473.e6
Open AccessSuccessful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature
- 14 April 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (1) , 146-153
Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI
Objectives: High‐dose total body irradiation (TBI) is considered a cornerstone of myeloablative conditioning for allogeneic stem cell transplantation (allo‐SCT). We retrospectively compared the main outcomes of an HLA matched or 1‐allele mismatched related or unrelated allo‐SCT in adult patients affected by acute leukemia (AL) or myelodysplastic syndromes (MDS).Methods: Fifty‐nine patients received cyclophosphamide (Cy)‐TBI (13.5 Gy) and graft‐versus‐host disease (GVHD) prophylaxis with a calcineurin‐inhibitor plus methrotrexate (CyTBI group) and 28 patients received fludarabine‐TBI (8.8–13.5 Gy) and GVHD prophylaxis with PTCy and tacrolimus (FluTBI‐PTCy group).Results: Median follow‐up for survivors was 82 and 22 months. The 12‐month probability of overall survival and progression‐free survival were similar (p = .18, p = .7). The incidence of Grades 2–4 and 3–4 acute GVHD, and the incidence of moderate‐to‐severe chronic GVHD were higher in the CyTBI group (p = .02, p < .01and p = .03). Nonrelapse mortality (NRM) at 12 months posttransplant was higher in the CyTBI group (p = 0.05), while the incidence of relapse was similar in both groups (p = 0.7). The number of GVHD‐free and relapse‐free patients without systemic immunosuppression (GRFS) at 1‐year posttransplant was higher in the FluTBI‐PTCy group (p = 0.01).Conclusions: The study confirms the safety and efficacy of a novel FluTBI‐PTCy platform with reduced incidence of severe acute and chronic GVHD, and early improvement of NRM.
- 14 April 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (1) , 146-153
Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI
Objectives: High‐dose total body irradiation (TBI) is considered a cornerstone of myeloablative conditioning for allogeneic stem cell transplantation (allo‐SCT). We retrospectively compared the main outcomes of an HLA matched or 1‐allele mismatched related or unrelated allo‐SCT in adult patients affected by acute leukemia (AL) or myelodysplastic syndromes (MDS).Methods: Fifty‐nine patients received cyclophosphamide (Cy)‐TBI (13.5 Gy) and graft‐versus‐host disease (GVHD) prophylaxis with a calcineurin‐inhibitor plus methrotrexate (CyTBI group) and 28 patients received fludarabine‐TBI (8.8–13.5 Gy) and GVHD prophylaxis with PTCy and tacrolimus (FluTBI‐PTCy group).Results: Median follow‐up for survivors was 82 and 22 months. The 12‐month probability of overall survival and progression‐free survival were similar (p = .18, p = .7). The incidence of Grades 2–4 and 3–4 acute GVHD, and the incidence of moderate‐to‐severe chronic GVHD were higher in the CyTBI group (p = .02, p < .01and p = .03). Nonrelapse mortality (NRM) at 12 months posttransplant was higher in the CyTBI group (p = 0.05), while the incidence of relapse was similar in both groups (p = 0.7). The number of GVHD‐free and relapse‐free patients without systemic immunosuppression (GRFS) at 1‐year posttransplant was higher in the FluTBI‐PTCy group (p = 0.01).Conclusions: The study confirms the safety and efficacy of a novel FluTBI‐PTCy platform with reduced incidence of severe acute and chronic GVHD, and early improvement of NRM.